Abstract | BACKGROUND: OBJECTIVE: METHODS: A review of the literature was carried out using PubMed. Current Phase I protocols using milatuzumab are summarized. RESULTS/CONCLUSION:
|
Authors | Tomer Mark, Peter Martin, John P Leonard, Ruben Niesvizky |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 18
Issue 1
Pg. 99-104
(Jan 2009)
ISSN: 1744-7658 [Electronic] England |
PMID | 19053886
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antigens, Differentiation, B-Lymphocyte
- Histocompatibility Antigens Class II
- invariant chain
- milatuzumab
|
Topics |
- Animals
- Antibodies, Monoclonal
(adverse effects, immunology, pharmacokinetics, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antigens, Differentiation, B-Lymphocyte
(immunology)
- Clinical Trials as Topic
- Drug Evaluation, Preclinical
- Histocompatibility Antigens Class II
(immunology)
- Humans
- Immunotherapy
- Lymphoma
(drug therapy, immunology)
|